Rabbit Oxytocin Antibodies (BRD)

Welcome to Woomera Therapeutics!

Rabbit Oxytocin  Antibodies (BRD)

This is an antibody preparation generated in rabbit by Dr. William North Professor of Physiology and Neurobiology of Dartmouth Medical School (now Geisel  Medical School at Dartmouth) using oxytocin coupled to bovine thyroglobulin.

Specificity:  Less than 0.1% cross-reactivity with vasopressin, and less than 0.5% with vasotocin,  in RIA

Tested Applications                        IHC-formaldehyde fixed tissues, Flow cytometry, RIA, ELISA


Form                                              Liquid

Storage Instructions                      Shipped at 4⁰C. Store at 4⁰C short term (1-2 weeks). Upon delivery aliquot and store at -20⁰C or                                                           -80⁰C. Avoid    freeze/Thaw cycling.

Storage buffer                               Preservative none -Stable if stored as 1:100 dilutions in PBS containing 1.25 mg/ml of BSA at                                                               -20⁰C.

                                                      Constituents: Whole serum

Purity                                            Whole Antiserum

Clonality                                       Polyclonal

Isotype                                         IgG, Behaves chromatographically like mouse IgG2B

Research Areas:                          Neuroscience, Endocrinology, Neuropeptides, Hormones, Neuroendocrinology, OBGYN, Cancer



Woomera Therapeutics Inc.  guarantees use of BRG in each of the tested applications:

The application information recommends certain starting dilutions; however, optimal dilutions/concentrations should be determined by the end user.


IHC                                                Use at an assay dependent concentration

RIA                                                1/30,000-99,000. Sensitivity to 0.2 pg/ml; <0.1% AVP cross-reaction.

ELISA                                            1/30,000-50,000

Flow Cytometry                             1/1000-5000

Western                                         1/1000-5000


North, W.G.  Neuropeptide production by small-cell carcinoma:  Vasopressin and oxytocin as plasma markers of disease.  J. Clin. Endocrin. Metab. 73:1316-1320, 1991.

Cheng, S.W.T., and North, W.G.  Absence of negative feedback by oxytocin on release from magnocellular neurones in conscious rats.  Can. J. Physiol. Pharmacol.  70(1):100-105, 1992.

North, W.G., Harbaugh, R., and Reeder, T.  An evaluation of human neurophysin production in Alzheimer's disease:  Preliminary observations.  Neurobiol. Aging  13(2):261-265, 1992.

Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., et al.  The role of central oxytocin in obsessive compulsive disorder and related normal behavior.  Psychoneuroendocrinology  19:723-749, 1994.

Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., Price, L.H., et al.  Elevated CSF levels of oxytocin in obsessive compulsive disorder: comparison with Tourette's syndrome and healthy controls.  Archives of Gener. Psychiatry 51:782-792, 1994.

Martin, A., State, M., Anderson, G.M., Kaye, W.M., Hanchett, J.M., McConaha, C.W., North, W.G., and Leckman, J.F.  Cerebrospinal Fluid of Oxytocin in Prader-Willi Syndrome: A Preliminary Report.  Soc. Biol. Psych.  44: 1349-1352, 1998.

Martin, A., State, M., Koenig, K., Schultz, R., Dykens, E.M., Cassidy, S.B., and Leckman, J.F.  Prader-Willi Syndrome.  Am. J. Pysch.  155: 1265-1273, 1998.  

Piqueux, C., Hagelstein M.T., Keegan, B., Legros, V., and North, W.G. Vasopressin and Oxytocin mitogen transduction pathway in small cell lung cancer cells.  Endocr.-Relat. Cancer, 4:871-875, 2004.


Product Code                   BRD